Sellas Life Sciences shares surge 175% after cancer vaccine succeeds in late-stage trial
Sellas Life Sciences (Nasdaq: SLS) shares rose 175% to $20.54 after its cancer vaccine, galinpepimut-S, met primary goals in a late-stage trial, extending survival in acute myeloid leukaemia patients. The vaccine reduced death risk by 41% and showed median survival of 24 months. Sellas plans to discuss accelerated FDA filing. Results are not yet approved.
How this was made

The 30-second read
Why it matters
The pivotal phase 3 readout is a direct valuation catalyst, and the company’s stated plan to meet the FDA about an accelerated filing strategy increases the probability of near-term regulatory momentum.
Market read
Traders can reassess probability-weighted approval odds and near-term catalysts (FDA meeting, BLA timing) based on the reported survival benefit and the magnitude of the market reaction.
What to watch
The article notes further analysis and future conference/publication; traders may need to wait for secondary endpoint clarity, subgroup consistency, and any manufacturing or CMC considerations ahead of the accelerated filing discussion.
Background
Sellas is developing galinpepimut-S (GPS) for acute myeloid leukemia patients in second or later remission who cannot undergo stem-cell transplant.
Ticker impact
Sellas Life Sciences shares surged after its phase 3 REGAL trial met the primary goal, cutting AML death risk by 41% versus control.
Likely further upside pressure as traders price in accelerated regulatory progress, tempered by skepticism around investigational status and pending conference/publication details.
The article reports statistically significant phase 3 survival benefit, a large same-day move, and explicit next regulatory steps (FDA meeting and BLA prep), which are direct catalysts for valuation and positioning.
Market effects
Reinforces risk appetite for AML and oncology vaccine platforms, potentially lifting sentiment for adjacent late-stage biotech programs.
Primarily US biotech sentiment, with Nasdaq small/mid-cap momentum effects from a large single-name surge.
Limited direct global spillover beyond oncology investor sentiment, unless follow-on conference/publication details shift broader expectations.
Counterpoint
Even with positive phase 3 survival, investors may over-discount regulatory risk; FDA could require additional evidence or question endpoint robustness, leading to post-pop mean reversion.
Key entities
- companySellas Life Sciences Group
Nasdaq-listed biotech whose phase 3 REGAL trial results drove a sharp share-price surge.
- productGalinpepimut-S (GPS)
Experimental cancer vaccine evaluated in the phase 3 REGAL study.
- regulatorUS Food and Drug Administration (FDA)
Regulatory body Sellas plans to meet to discuss an accelerated regulatory filing strategy.

